Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL616961 | 0.78 | CRHBP (0.47) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL27971838 | 0.78 | CYP19A1 (0.45) | ALDH1A1CYP11B1CYP11B2CYP19A1CYP3A4 | |
| SCHEMBL29935616 | 0.78 | CYP1A2 (0.47) | KDM4EALDH1A1SMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL28030309 | 0.78 | CYP19A1 (0.43) | CYP11B1CYP11B2CYP19A1CYP3A4CYP2C19 | |
| SCHEMBL30480716 | 0.78 | CRHBP (0.47) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12905110 | 0.78 | CYP19A1 (0.43) | CYP11B1CYP11B2CYP19A1CYP3A4CYP2C19 | |
| SCHEMBL1956908 | 0.78 | ALDH1A1 (0.46) | KDM4EALDH1A1SMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL1957646 | 0.75 | ALDH1A1 (0.51) | KDM4EALDH1A1SMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL1956919 | 0.74 | MAOB (0.47) | KDM4EALDH1A1SMN1; SMN2CYP19A1CYP3A4 | |
| SCHEMBL1610377 | 0.74 | ALDH1A1 (0.54) | KDM4EALDH1A1SMN1; SMN2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108341799-B | Novel indole derivatives for the treatment of cancer, viral infections and lung diseases | 生物控制术公司 | 2022-01-25 | — | — | CN | disclosed |
| US-10851054-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | BIOKINESIS (FR) | 2020-12-01 | — | — | US | disclosed |
| US-10851054-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | BIOKINESIS (FR) | 2020-12-01 | — | — | US | disclosed |
| US-20190169124-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | DIACCURATE (FR) | 2019-06-06 | — | — | US | disclosed |
| US-20190169124-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | DIACCURATE (FR) | 2019-06-06 | — | — | US | disclosed |
| US-10189782-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | BIOKINESIS (FR) | 2019-01-29 | — | — | US | disclosed |
| US-10189782-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | BIOKINESIS (FR) | 2019-01-29 | — | — | US | disclosed |
| US-20170233342-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | DIACCURATE (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170233342-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | DIACCURATE (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170233342-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | DIACCURATE (FR) | 2017-08-17 | — | — | US | disclosed |
| EP-2509975-B1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2014-04-23 | — | — | EP | disclosed |
| US-8420655-B2 | Benzimidazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-8420655-B2 | Benzimidazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-8420655-B2 | Benzimidazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2509975-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | Boehringer Ingelheim International GmbH (DE) | 2012-10-17 | — | — | EP | disclosed |
| US-20110301161-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301161-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301161-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| WO-2011068821-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011068821-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301161-A1 | BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTC4S, LTB4R, LTB4R2 | KDM4E 1908/4885ALDH1A1 552/4885SMN1; SMN2 3639/4885 |
| US-20190169124-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | IDO2, IDO1, ING2 | KDM4E 1505/4885ALDH1A1 2891/4885SMN1; SMN2 4692/4885 |
| US-10189782-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | IDO2, IDO1, ING2 | KDM4E 1237/4885ALDH1A1 2533/4885SMN1; SMN2 4705/4885 |
| US-20170233342-A1 | NEW DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER, VIRAL INFECTIONS AND LUNG DISEASES | IDO2, IDO1, ING2 | KDM4E 1505/4885ALDH1A1 2891/4885SMN1; SMN2 4692/4885 |
| US-10851054-B2 | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | IDO2, IDO1, ING2 | KDM4E 1237/4885ALDH1A1 2533/4885SMN1; SMN2 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.